Ustekinumab regulatory update

FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 11-0 to recommend approval of a BLA from Johnson & Johnson for ustekinumab to treat moderate-to-severe plaque psoriasis. However, the c...